Publications by authors named "David Brachman"

Claim this Profile
A
A biologically effective dose-based framework for integrating LDR brachytherapy and EBRT in glioblastoma treatment.
Adam C Turner, Elliot M Abbott, Michael A Garcia, Sita Patel, Kimberly M Johnson, David G Brachman

Brachytherapy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
Michael A Garcia, Adam Turner, David G Brachman

J Neurooncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial.
Kris Smith, Peter Nakaji, Theresa Thomas, Dilini Pinnaduwage, Garrick Wallstrom, David Brachman

Neuro Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors.
Dilini S Pinnaduwage, Shiv P Srivastava, Xiangsheng Yan, Shyam Jani, David G Brachman

Technol Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).
Jeffrey S Wefel, Terri S Armstrong, Stephanie L Pugh, Mark R Gilbert, Merideth M Wendland, David G Brachman

Neuro Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resection and Surgically Targeted Radiation Therapy for the Treatment of Larger Recurrent or Newly Diagnosed Brain Metastasis: Results From a Prospective Trial.
Peter Nakaji, Kris Smith, Emad Youssef, Theresa Thomas, Dilini Pinnaduwage, David Brachman

Cureus· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Erica H Bell, Peixin Zhang, Edward G Shaw, Jan C Buckner, Geoffrey R Barger, David G Brachman

J Clin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas.
David G Brachman, Emad Youssef, Christopher J Dardis, Nader Sanai, Joseph M Zabramski

J Neurosurg· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.
William A Hall, Stephanie L Pugh, Jeffrey S Wefel, Terri S Armstrong, Mark R Gilbert, David G Brachman

Neurosurgery· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Robert M Meier, Daniel A Bloch, Cristian Cotrutz, Alan C Beckman, George T Henning, David G Brachman

Int J Radiat Oncol Biol Phys· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
Leland Rogers, Peixin Zhang, Michael A Vogelbaum, Arie Perry, Lynn S Ashby, David Brachman

J Neurosurg· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Deborah T Blumenthal, Minhee Won, Minesh P Mehta, Mark R Gilbert, Paul D Brown, David G Brachman

Neuro Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, David G Brachman

Lancet· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, Mark R Gilbert, Minesh Mehta, David Brachman

JAMA Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Susan Chang, Peixin Zhang, J Gregory Cairncross, Mark R Gilbert, Jean-Paul Bahary, David Brachman

Neuro Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.
C Leland Rogers, Arie Perry, Stephanie Pugh, Michael A Vogelbaum, David Brachman

Neuro Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, David Brachman

N Engl J Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Reply to Brown et al.
David G Brachman

Int J Radiat Oncol Biol Phys· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Michael A Vogelbaum, Chen Hu, David M Peereboom, David R Macdonald, Caterina Giannini, David G Brachman

J Neurooncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
David G Brachman, Stephanie L Pugh, Lynn S Ashby, Theresa A Thomas, Erin M Dunbar

Int J Radiat Oncol Biol Phys· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Barbara J Fisher, Chen Hu, David R Macdonald, Glenn J Lesser, Stephen W Coons, David G Brachman

Int J Radiat Oncol Biol Phys· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial.
Karen E Hoffman, Stephanie L Pugh, Jennifer L James, Charles Scarantino, Benjamin Movsas, David G Brachman

Qual Life Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
Mark E Oppenlander, Andrew B Wolf, Laura A Snyder, Robert Bina, Jeffrey R Wilson, David Brachman

J Neurosurg· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, David G Brachman

N Engl J Med· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis